Sickle cell disease: New insights into pathophysiology and treatment

Pediatric Annals

Volumn 37, Issue 5, 2008, Pages 311-321

  Inati, Adlette ^a,b,c   Koussa, Suzan ^b   Taher, Ali ^d   Perrine, Susan ^e  

^a RAFIC HARIRI UNIVERSITY HOSPITAL   (Lebanon)

^b Chronic Care Center Hazmieh   (Lebanon)

^c UNIVERSITY OF BALAMAND   (Lebanon)

^d AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^e BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANALGESIC AGENT; ARGININE; BUTYRIC ACID; CARNITINE; CODEINE; FENTANYL; HEMOGLOBIN S; HYDROXYUREA; IRON CHELATING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; SILDENAFIL; VASODILATOR AGENT;

ACUTE CHEST SYNDROME; ACUTE SPLENIC SEQUESTRATION; APLASTIC ANEMIA; BETA THALASSEMIA; BLOOD SMEAR; BLOOD VESSEL OCCLUSION; CLINICAL FEATURE; CLINICAL TRIAL; CYTOPENIA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG MECHANISM; DRY SKIN; ERYTHROCYTE TRANSFUSION; GEL ELECTROPHORESIS; GENETIC DISORDER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOGLOBIN SC DISEASE; HEMOLYSIS; HUMAN; HYPERPIGMENTATION; INFECTION; MORBIDITY; MORTALITY; PAIN; PATHOPHYSIOLOGY; PRIAPISM; PUBLIC HEALTH PROBLEM; PULMONARY HYPERTENSION; REVIEW; SICKLE CELL ANEMIA; SIDE EFFECT; SPERMATOGENESIS; SPLEEN DISEASE; STROKE; SURVIVAL;

EID: 45349108763     PISSN: 00904481     EISSN: None     Source Type: Journal    
DOI: 10.3928/00904481-20080501-07     Document Type: Review

References (60)

1. Pauling L, Itano HA, et al. Sickle cell anemia: a molecular disease. Science. 1949;110(2835):543-548.
2. Ingram VM. Gene mutations in human haemoglobin: the chemical difference between normal and sickle haemoglobin. Nature. 1957;180(4581):326-328.
3. MJ Stuart, RL Nagel. Sickle cell disease. Lancet. 2004;364:1343-1360.
4. Frenette PS, Atweh GF. Sickle cell disease: old discoveries, new concepts, and future promise. Clin Invest. 2007;117(4):850-858.
5. Chiang EY, Frenette PS. Sickle cell vasoocclusion. Hematol Oncol Clin North Am. 2005;19(5):771-784.
6. Kuypers FA. Membrane lipid alterations in hemoglobinopathies. Hematology Am Soc Hematol Educ Program. 2007;2007:68-73.
7. Telen MJ. Role of adhesion molecules and vascular endothelium in the pathogenesis of sickle cell disease. Hematology Am Soc Hematol Educ Program. 2007;2007:84-90.
8. Finnegan EM, Barabino GA, Liu XD, Chang HY, Jonczyk A, Kaul DK. Small-molecule cyclic alpha V beta 3 antagonists inhibit sickle red cell adhesion to vascular endothelium and vasoocclusion. Am J Physiol Heart Circ Physiol. 2007;293(2):H1038-1045.
9. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med. 1994;330(23):1639-1644.
10. Inati A, Jradi O, Tarabay H, et al. Sickle cell disease: the Lebanese experience. Int J Lab Hematol. 2007;29(6):399-408.
11. Reiter CD, Wang X, Tanus-Santos JE, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle cell disease. Nat Med. 2002;8(12):1383-1389.
12. Gladwin MT, Schechter A, Ognibene FP, et al. Divergent nitric oxide bioavailability in men and women with sickle cell disease. Circulation. 2003;107(2):271-278.
13. Loscalzo J. Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ Res. 2001;88(8):756-762.
14. Morris CR, Kato GJ, Poljakovic M, et al. Dysregulated arginine metabolism, hemolysis-Associated pulmonary hypertension and mortality in sickle cell disease. JAMA. 2005;294(1):81-90.
15. Kato GJ, Gladwin MT. Hemolysis-associated pulmonary hypertension in sickle cell disease and thalassemia. EHA. 2007.
16. Serjeant GR. Natural history and determinants of clinical severity of sickle cell disease. Curr Opin Hematol. 1995;2(2):103-108.
17. Quinn CT, Rogers ZR, Buchanan GR. Survival of children with sickle cell disease. Blood. 2004;103(11):4023-4027.
18. Telfer P, Coen P, Chakravorty S, Wilkey O, et al. Clinical outcomes in children with sickle cell disease living in England: a neonatal cohort in East London. Haematologica. 20071;92(7):905-912.
19. Ballas SK. Current issues in sickle cell pain and its management. Hematology Am Soc Hematol Educ Program. 2007;2007:97-105.
20. Vichinsky EP, Styles LA, Colangelo H, Wright EC, Castro O, Nickerson B. Acute chest syndrome in sickle cell disease: clinical presentation and course. Blood. 1997;89(5):1787-1792.
21. Vichinsky EP, Neumayr LD, Earles AN, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. N Engl J Med. 2000;342(25):1855-1865.
22. Boyd JH, Macklin EA, Strunk RC, DeBaun MR. Asthma is associated with acute chest syndrome and pain in children with sickle cell anemia. Blood. 2006; 108(9):2923-2927.
23. Styles LA, Aarsman AJ, Vichinsky EP, Kuypers FA. Secretory phospholipase A(2) predicts impending acute chest syndrome in sickle cell disease. Blood. 2000;9(9):3276-3278.
24. Tamouza R, Busson M, Fortier C, et al. HLA-E*0101 allele in homozygous state favors severe bacterial infections in sickle cell anemia. Hum Immunol. 2007;68(10):849-853.
25. Halasa NB, Shankar SM, Talbot TR, et al. Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine. Clin Infect Dis. 2007;44(11):1428-1433.
26. Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood. 1998;91(1):288-294.
27. Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial doppler ultrasonography. N Engl J Med. 1998;339(1):5-11.
28. Miller ST, Macklin EA, Pegelow CH, et al. Silent infarction as a risk factor for overt stroke in children with sickle cell anemia: a report from the Cooperative Study of sickle cell disease. J Pediatr. 2001;139(3):385-390.
29. Hoppe C, Klitz W, D'Harlingue K, et al; for the Stroke Prevention Trial in Sickle Cell Anemia (STOP) Investigators. Confirmation of an association between the TNF (-308) promoter polymorphism and stroke risk in children with sickle cell anemia. Stroke. 2007;38(8):2241-2246.
30. Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med. 2004;350(9):886-895.
31. Haque AK, Gokhale S, Rampy BA, Adegboyega P, Duarte A, Saldana MJ. Pulmonary hypertension in sickle cell hemoglobinopathy: a clinicopathologic study of 20 cases. Hum Pathol. 2002;33(10):1037-1043.
32. Anthi A, Machado RF, Jison ML, et al. Hemodynamic and functional assessment of patients with sickle cell disease and pulmonary hypertension. Am J Respir Crit Care Med. 2007;175(12):1272-1279.
33. Nolan VG, Wyszynski DF, Farrer LA, Steinberg MH. Hemolysis-associated priapism in sickle cell disease. Blood. 2005;106(9):3264-2367.
34. Perrine RP, Pembrey ME, John P, Perrine S, Shoup F. Natural history of sickle cell anemia in Saudi Arabs. A study of 270 subjects. Ann Intern Med. 1978;88(1):1-6.
35. Miller ST, Sleeper LA, Pegelow CH, et al. Prediction of adverse outcomes in children with sickle cell disease. N Engl J Med. 2000;342(2):83-89
36. Boyd JH, Macklin EA, Strunk RC, DeBaun MR. Asthma is associated with increased mortality in individuals with sickle cell anemia. Haematologica. 2007;92(8):1115-1118.
37. Platt OS, Orkin SH, Dover G, Beardsley GP, Miller B, Nathan DG. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest. 1984;74(2):652-656.
38. Charache S, Dover GJ, Moore Rd, et al. Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia. Blood. 1992;79(10):2555-2565.
39. Iyamu EW, Cecil R, Parkin L, Woods G, Ohene-Frempong K, Asakura T. Modulation of erythrocyte arginase activity in sickle cell disease patients during hydroxyurea therapy. Br J Haematol. 2005;131(3):389-394.
40. Cokic VP, Smith RD, Beleslin-Cokic BB, et al. Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase. J Clin Invest. 2003;111(2):231-239.
41. Saleh AW, Hillen HF, Duits AJ. Levels of endothelial, neutrophil and platelet-specific factors in sickle cell anemia patients during hydroxyurea therapy. Acta Haematol. 1999;102(1):31-37.
42. Charache S, Terrin, ML, Moore RD, et al. Effect of hydroxyurea on frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med. 1995;332(2):1317-1322.
43. Steinberg MH, Barton F, Castro O, et al. 2003. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA. 289(13):1645-1651.
44. Hankins JS, Ware RE, Rogers ZR, et al. Long-term hydroxyurea therapy for infants with sickle cell anemia - the Husoft extension study. Blood. 2005;106(7):2269-2275.
45. Kinney TR, Helms RW, O'Branski EE, et al. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood. 1999;94(5):1550-1554.
46. Gulbis B, Haberman D, Dufour D, et al. Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events: the Belgian experience. Blood. 2005;105(7):2685-2690.
47. Hankins JS, Helton KJ, McCarville MB, Li CS, Wang WC, Ware RE. Preservation of spleen and brain function in children with sickle cell anemia treated with hydroxyurea. Pediatr Blood Cancer. 2008;50(2):293-297.
48. Zimmerman SA, Schultz WH, Burgett S, Mortier NA, Ware RE. Hydroxyurea therapy lowers transcranial doppler flow velocities in children with sickle cell anemia. Blood. 2007;110(3):1043-1047.
49. Vichinsky EP, ed. Transfusion-related iron overload in sickle cell anemia. Semin Hematol. 2001;38(Suppl 1):1-84.
50. Panepinto JA, Walters MC, Carreras J, et al; Non-Malignant Marrow Disorders Working Committee, Center for International Blood and Marrow Transplant Research. Matched-related donor transplantation for sickle cell disease: report from the Center for International Blood and Transplant Research. Br J Haematol. 2007;137(5):479-485.
51. Bernaudin F, Socie G, Kuentz M, et al. Long-term results of related, myeloablative stem cell transplantation to cure sickle cell disease. Blood. 2007;110(7):2749-2756.
52. Weinberg RS, Ji X, Sutton M, Perrine S, et al. Butyrate increases the efficiency of translation of gamma-globin mRNA. Blood. 2005;105(4):1807-1809.
53. DeSimone J, Koshy M, Dorn L, et al. 2002. Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia. Blood. 2002;9(11):3905-3908.
54. Ballas SK. Pain management of sickle cell disease. Hematol Oncol Clin North Am. 2005;19(5):785-802.
55. Givens M, Rutherford C, Joshi G, Delaney K. Impact of an emergency department pain management protocol on the pattern of visits by patients with sickle cell disease. J Emerg Med. 2007;32(3):239-243.
56. Machado RF, Martyr S, Kato GJ, et al. Sildenafil therapy in patients with sickle cell disease and pulmonarybhypertension. Br J Haematol. 2005;130(3):445-453.
57. Steinberg MH. Management of sickle cell disease. N Engl J Med. 1999;340(13):1021-1030.
58. Burnett AL, Bivalacqua TJ, Champion HC, Musicki B. Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism. Urology. 2006;67(5):1043-1048.
59. Inati A, Zeineh N, Isma'eel H, Koussa S, Gharzuddine W, Taher A. Beta-thalassemia: the Lebanese experience. Clin Lab Haematol. 2006;28(4):2172-27.
60. Cao A. Results of programmes for antenatal detection of thalassemia in reducing the incidence of the disorder. Blood Rev. 1987;1(3):169-176.